Loading stock data…
ARVN
$7.03-0.18 (-2.50%)
Market OpenUpdated 3:08 PM EDT
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arvinas, Inc. in the Healthcare sector is trading at $7.03. Wall Street consensus targets $15.00 (16 analysts), implying a +113.4% move over the next 12 months. The stock is currently near its 52-week low of $6.06, remaining 34.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +113.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.60M↑ | $9.50M↓ | $41.90M↑ | $22.40M↓ | $188.80M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$63.80M↑ | -$74.60M↓ | -$43.80M↑ | -$71.50M↓ | $71.40M |
| Net Income | -$57.60M↑ | -$67.40M↓ | -$35.10M↑ | -$61.20M↓ | $82.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degrad...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.21%
Volume
Today's trading volume
410,155
Recent News
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Celebrations may be in order for Arvinas, Inc. ( NASDAQ:ARVN ) shareholders, with the analysts delivering a significant...
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders are probably feeling a little disappointed, since its shares fell 3.8% to...
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?
Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which was approved in May 2026 following positive Phase 3 VERITAC-2 data. A key nuance is that Rigel assumes worldwide commercialization rights, including the option to sublicense outside the U.S., while Arvinas and...